[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

US20040186050A1 - Method for orally administering parathyroid hormone (pth) - Google Patents

Method for orally administering parathyroid hormone (pth) Download PDF

Info

Publication number
US20040186050A1
US20040186050A1 US10/478,631 US47863104A US2004186050A1 US 20040186050 A1 US20040186050 A1 US 20040186050A1 US 47863104 A US47863104 A US 47863104A US 2004186050 A1 US2004186050 A1 US 2004186050A1
Authority
US
United States
Prior art keywords
pth
calcitonin
effective amount
oral administration
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/478,631
Other languages
English (en)
Inventor
Joseph Ault
Moise Azria
Simon Bateman
James McLeod
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23136525&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20040186050(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of US20040186050A1 publication Critical patent/US20040186050A1/en
Priority to US12/020,700 priority Critical patent/US8153587B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Definitions

  • the present invention relates to the oral delivery of parathyroid hormone (PTH). More particularly, the invention is directed to the use of calcitonin in combination with PTH for the oral administration of PTH.
  • PTH parathyroid hormone
  • the therapeutic window for oral PTH therapy could be increased.
  • calcitonins reduce serum calcium concentrations by interacting directly with osteoclasts resulting in reduction in the bone resorptive surface area by osteoclasts and reduction in net bone resorption. Due to a decrease in plasma calcium concentration there is a corresponding decrease in urinary calcium concentrations, a known risk factor for nephrolithiasis.
  • the present invention describes a method for orally administering PTH which broadens the therapeutic window for PTH administration and allows for the oral administration of greater PTH dosages without the potentially toxic hypercalcemic side effects.
  • the present invention is directed to a method for orally administering an effective dose of PTH comprising orally co-administering to a patient in need of PTH an effective amount of a PTH and an effective amount of a calcitonin.
  • calcitonin Administering calcitonin with PTH therapy allows the additional therapeutic effects of the presently precluded PTH doses without the hypercalcemic side effects. Additionally, the calcitonin provides an analgesic effect which is useful in off-setting the bone pain usually associated with administration of PTH.
  • the invention is also directed to a method of stimulating new bone formation comprising orally administering to a patient in need of new bone formation a therapeutically effective amount of a PTH and a therapeutically effective amount of a calcitonin.
  • the invention is directed to a method of treatment or prevention of osteoporosis comprising orally administering to a patient in need of said treatment or prevention a therapeutically effective amount of a PTH and a therapeutically effective amount of a calcitonin.
  • the invention is also directed to a composition suitable for oral delivery comprising a PTH and a calcitonin, e.g. for simultaneous, concurrent or sequential administration of the PTH and calcitonin.
  • the invention is further directed to use of PTH and calcitonin for the preparation of an orally administrable medicament for the stimulation of new bone formation, e.g. for simultaneous, concurrent or sequential oral administration of the PTH and calcitonin.
  • the invention is yet further directed to a kit for the stimulation of new bone formation comprising PTH and calcitonin suitable for oral administration together with instructions for the oral administration thereof, e.g. for simultaneous, concurrent or sequential oral administration of the PTH and calcitonin.
  • the parathyroid hormone or PTH can be the full length, 84 amino acid form of parathyroid hormone, e.g. the human form, hPTH (1-84), or any polypeptide, protein, protein fragment, or modified fragment, i.e. PTH-related peptides and PTH analogs, capable of mimicing the activity of hPTH (1-84) in controlling calcium and phosphate metabolism to build bone in the human body.
  • the PTH fragments will generally incorporate at least the first 28 N-terminal residue and include PTH (1-28), PTH (1-31), PTH (1-34), PTH (1-37), PTH (1-38) and PTH (1-41) or analogues thereof, e.g. PTS893.
  • the PTH can be a single PTH or any combination of two or more PTHs.
  • the calcitonin for use in the instant invention can be any calcitonin, including natural, synthetic or recombinant sources thereof, as well as calcitonin derivatives such as 1,7-Asn-eel calcitonin.
  • calcitonins including salmon, pig and eel calcitonin are commercially available and commonly employed for the treatment of e.g. Paget's disease, hypercalcemia of malignancy and osteoporosis.
  • the calcitonin can comprise a single calcitonin or any combination of two or more calcitonins.
  • the preferred calcitonin is synthetic salmon calcitonin.
  • the calcitonins are commercially available or may be obtained by known methods.
  • the amount of PTH to be administered is generally an amount effective to stimulate new bone formation i.e. a therapeutically effective amount. This amount will necessarily vary with the age, size, sex and condition of the subject to be treated, the nature and severity of the disorder to be treated and the like. However, the amount can be less than that amount when a plurality of the compositions are to be administered, i.e., the total effective amount can be administered in cumulative dosage units. The amount of PTH can also be more than the effective amount when the composition provides sustained release of the pharmacologically active agent. The total amount of PTH to be used can be determined by methods known to those skilled in the art. However, in general, satisfactory results will be obtained systemically at daily dosages of from about 0.001 ⁇ g/kg to about 10 mg/kg animal body weight, preferably 1 ⁇ g/kg to about 6 ⁇ g/kg body weight.
  • calcitonin to be administered will, of course, vary depending upon, for example, the amount of PTH to be administered and the severity of the condition being treated. However, in general, satisfactory results will be obtained systemically at daily dosages of from about 0.5 ⁇ g/kg to about 10 ⁇ g/kg animal body weight, preferably 1 ⁇ g/kg to about 6 ⁇ g/kg body weight.
  • the oral administration can be accomplished regularly, e.g. once or more on a daily or weekly basis; intermittently, e.g. irregularly during a day or week; or cyclically, e.g. regularly for a period of days or weeks followed by a period without administration.
  • the co-administration of PTH and calcitonin includes simultaneous, concurrent, or sequential administration of the two compounds.
  • Simultaneous administration means administration of the two compounds in a single dosage form; concurrent administration means administration of the two compounds at about the same time but in separate dosage forms; and, sequential administration means administration of one of the compounds, after which the other is administered.
  • Sequential administration may also take the form of simultaneous or concurrent administration of the two compounds, followed by cessation of the simultaneous or concurrent administration and then continued administration of one of the two compounds alone.
  • the oral administration of the PTH and calcitonin according to the instant invention can be accomplished in any known manner, e.g. as a liquid or solid dosage forms.
  • the liquid dosage forms include solution emulsions, suspensions, syrups and elixirs.
  • the liquid formulations may also include inert excipients commonly used in the art such as, solubilizing agents such as ethanol; oils such as cottonseed, castor and sesame oils; wetting agents; emulsifying agents; suspending agents; sweeteners; flavorings; and solvent such as water.
  • the solid dosage forms include capsules, soft-gel capsules, tablets, caplets, powders, granules or other solid oral dosage forms, all of which can be prepared by methods well known in the art.
  • these solid dosage forms generally include a pharmaceutically acceptable delivery agent for the PTH and/or calcitonin.
  • Suitable delivery agents are any one of the 123 modified amino acids disclosed in U.S. Pat. No. 5,866,536 or any one of the 193 modified amino acids described in U.S. Pat. No. 5,773,647 or any combination thereof.
  • the contents of the aforementioned U.S. Pat. Nos. 5,773,647 and 5,866,536 are hereby incorporated by reference in their entirety.
  • the delivery agent can be the disodium salt of any of the aforementioned modified amino acids as well as ethanol solvates and hydrates thereof.
  • Suitable compounds include compounds of the following formula I
  • R 1 , R 2 , R 3 , and R 4 are independently hydrogen, —OH, —NR 6 R 7 , halogen, C 1 -C 4 alkyl, or C 1 -C 4 alkoxy;
  • R 5 is a substituted or unsubstituted C 2 -C 16 alkylene, substituted or unsubstituted C 2 -C 16 alkenylene, substituted or unsubstituted C 1 -C 12 alkyl(arylene), or substituted or unsubstituted aryl(C 1 -C 12 alkylene); and
  • R 6 and R 7 are independently hydrogen, oxygen, or C 1 -C 4 alkyl; and hydrates and alcohol solvates thereof.
  • the compounds of formula I as well as their disodium salts and alcohol solvates and hydrates thereof are described in WO 00/059863, along with methods for preparing them.
  • the preferred delivery agents are N-(5-chlorosalicyloyl)-8-aminocaprylic acid (5-CNAC), N-(10-[2-hydroxybenzoyl]amino)decanoic acid (SNAD), N-(8-[2-hydroxybenzoyl]amino)caprylic acid (SNAC) and their monosodium and disodium salts, ethanol solvates of their sodium salts and the monohydrates of their sodium salts and any combinations thereof.
  • the most preferred delivery agent is the disodium salt of 5-CNAC and the monohydrate thereof.
  • compositions of the present invention typically contain a delivery effective amount of one or more of the delivery agents, i.e. an amount sufficient to deliver the PTH and/or calcitonin for the desired effect.
  • the delivery agent is present in an amount of 2.5% to 99.4% by weight, more preferably 25% to 50% by weight of the total composition.
  • compositions may additionally comprise additives in amounts customarily employed including, but not limited to, a pH adjuster, a preservative, a flavorant, a taste-masking agent, a fragrance, a humectant, a tonicifier, a colorant, a surfactant, a plasticizer, a lubricant such as magnesium stearate, a flow aid, a compression aid, a solubilizer, an excipient, a diluent such as microcrystalline cellulose, e.g. Avicel PH 102 supplied by FMC corporation, or any combination thereof.
  • additives may include phosphate buffer salts, citric acid, glycols, and other dispersing agents.
  • composition may also include one or more enzyme inhibitors, such as actinonin or epiactinonin and derivatives thereof; aprotinin, Trasylol and Bowman-Birk inhibitor.
  • enzyme inhibitors such as actinonin or epiactinonin and derivatives thereof; aprotinin, Trasylol and Bowman-Birk inhibitor.
  • a transport inhibitor i.e. a ⁇ -glycoprotein such as Ketoprofin, may be present in the compositions of the present invention.
  • the solid pharmaceutical compositions of the instant invention can be prepared by conventional methods e.g. by blending a mixture of the active agent or active agents, the delivery agent, and any other ingredients, kneading, and filling into capsules or, instead of filling into capsules, molding followed by further tableting or compression-molding to give tablets.
  • a solid dispersion may be formed by known methods followed by further processing to form a tablet or capsule.
  • the ingredients in the pharmaceutical compositions of the instant invention are homogeneously or uniformly mixed throughout the solid dosage form.
  • the oral administration of the present invention may be to any animal in need thereof, including, but not limited to, mammals, such as rodents, cows, pigs, dogs, cats, and primates, particularly humans.
  • Capsules prepared from 400 mg 5-CNAC disodium salt/800 mcg sCT/800 mcg PTH (Capsule 1A)
  • Capsules prepared from 400 mg 5-CNAC disodium salt/800 mcg PTH (Capsule 1B)
  • the PTH is PTH fragment 1-34, commercially available.
  • the sCT is salmon calcitonin.
  • the capsules are all prepared as dry blends by weighing out the individual components blending them together to make a homogeneous mix and then hand filling 400 mg of the mix into each capsule. For the PTH only capsules, the PTH is weighed out and 400 mg placed directly into each capsule.
  • Example 1 The capsules prepared in Example 1 are administered to Rhesus monkeys as follows: four monkeys in a group are each dosed with one capsule prepared as in Example 1 as follows:
  • the Rhesus monkeys fast overnight prior to dosing and are restrained in chairs fully conscious, for the duration of the study period.
  • the capsules are administered via a gavage tube followed by 10 mL of water.
  • Plasma salmon calcitonin and plasma PTH are determined by radioimmunoassay.
  • the primate plasma salmon calcitonin (sCT) and PTH results from each group of monkeys are averaged and the maximum mean plasma calcitonin are calculated and reported in Tables 1-5 TABLE 1 SALMON CALCITONIN and PTH SCT PLASMA CONCENTRATIONS (pg/mL) AFTER ORAL ADMINISTRATION TO THE RHESUS MONKEY Dose: 1 Capsule 1A Animal Time [hours] no.
  • the sCT and PTH plasma levels are essentially the same whether the compounds are administered separately or together.
  • the oral administration of a combination of PTH and calcitonin while resulting in similar PTH and calcitonin plasma concentration levels as those attained upon administrations of each agent alone; quite surprisingly results in reduction of serum calcium concentrations to the level observed with calcitonin alone.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
US10/478,631 2001-06-01 2002-05-31 Method for orally administering parathyroid hormone (pth) Abandoned US20040186050A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/020,700 US8153587B2 (en) 2001-06-01 2008-01-28 Orally administering parathyroid hormone and calcitonin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29516901P 2001-06-01 2001-06-01
PCT/EP2002/006017 WO2002098453A2 (en) 2001-06-01 2002-05-31 Orally administering parathyroid hormone and calcitonin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/020,700 Continuation US8153587B2 (en) 2001-06-01 2008-01-28 Orally administering parathyroid hormone and calcitonin

Publications (1)

Publication Number Publication Date
US20040186050A1 true US20040186050A1 (en) 2004-09-23

Family

ID=23136525

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/478,631 Abandoned US20040186050A1 (en) 2001-06-01 2002-05-31 Method for orally administering parathyroid hormone (pth)
US12/020,700 Expired - Fee Related US8153587B2 (en) 2001-06-01 2008-01-28 Orally administering parathyroid hormone and calcitonin

Family Applications After (1)

Application Number Title Priority Date Filing Date
US12/020,700 Expired - Fee Related US8153587B2 (en) 2001-06-01 2008-01-28 Orally administering parathyroid hormone and calcitonin

Country Status (25)

Country Link
US (2) US20040186050A1 (de)
EP (1) EP1397156B1 (de)
JP (2) JP5073153B2 (de)
KR (3) KR20090116836A (de)
CN (2) CN1512892A (de)
AT (1) ATE356631T1 (de)
AU (2) AU2002344371B2 (de)
BR (1) BRPI0209748B1 (de)
CA (1) CA2446929C (de)
CO (1) CO5540323A2 (de)
CZ (1) CZ307145B6 (de)
DE (1) DE60218842T2 (de)
EC (1) ECSP034858A (de)
ES (1) ES2282436T3 (de)
HU (1) HU229613B1 (de)
IL (2) IL158777A0 (de)
MX (1) MXPA03011027A (de)
NO (1) NO330093B1 (de)
NZ (1) NZ529439A (de)
PL (1) PL211976B1 (de)
PT (1) PT1397156E (de)
RU (1) RU2300392C2 (de)
SK (1) SK287697B6 (de)
WO (1) WO2002098453A2 (de)
ZA (1) ZA200308625B (de)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050054557A1 (en) * 2002-05-09 2005-03-10 Goldberg Michael M. Compositions for delivering parathyroid hormone and calcitonin
US20070219132A1 (en) * 2005-11-10 2007-09-20 Board Of Control Of Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
WO2012130193A1 (en) 2011-03-31 2012-10-04 Zentiva, K.S. Non-covalent soluble complexes of teriparatide with polysaccharides and a dosage form of teriparatide for oral administration
US8987201B2 (en) 2009-12-07 2015-03-24 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
WO2018043942A1 (ko) * 2016-08-30 2018-03-08 목포대학교산학협력단 위장관 흡수증진제를 함유하는 부갑상선 호르몬의 경구 투여 제형

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ529439A (en) 2001-06-01 2005-11-25 Novartis Ag Method for orally administering parathyroid hormone (PTH)
MXPA04001418A (es) * 2001-08-17 2004-05-27 Novartis Ag Acido n-(5-clorosalociloil)-8-aminocaprilico como agente de suministro oral para fragmentos de hormona paratiroides.
CN101627011A (zh) 2005-09-19 2010-01-13 爱密斯菲尔科技公司 N-(5-氯水杨酰基)-8-氨基辛酸的二钠盐的晶形
GB0522566D0 (en) * 2005-11-04 2005-12-14 Novartis Ag Organic compounds
AU2006318815B2 (en) * 2005-11-17 2010-08-19 Novartis Ag Pharmaceutical composition
PT2215047E (pt) 2007-11-02 2014-01-20 Emisphere Tech Inc Processo para o tratamento da deficiência de vitamina b12
CA2734442C (en) 2008-08-18 2016-08-16 Oramed Ltd Methods and compositions for oral administration of proteins
CN104857505A (zh) * 2008-08-18 2015-08-26 安特拉贝欧有限公司 用于口服给予蛋白质的方法和组合物
CN104800564A (zh) * 2015-04-02 2015-07-29 中国人民解放军济南军区总医院 一种治疗血虚不荣型甲状旁腺功能减退症的中药组合物
KR102163445B1 (ko) 2017-11-20 2020-10-07 주식회사 노브메타파마 Chp(사이클로-히스프로)를 포함하는 골 손실 질환의 예방, 개선 또는 치료용 조성물
KR102115353B1 (ko) * 2019-05-17 2020-05-26 주식회사 노브메타파마 Chp(사이클로-히스프로) 및 부갑상선 호르몬을 포함하는 골 손실 질환의 예방, 개선 또는 치료용 조성물

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4692433A (en) * 1983-10-12 1987-09-08 The Regents Of The University Of California Method and composition for regulating serum calcium levels of mammals
US5364840A (en) * 1989-12-05 1994-11-15 Vical, Inc. Synthetic calcitonin peptides
US5620708A (en) * 1993-02-22 1997-04-15 Alza Corporation Compositions and methods for the oral delivery of active agents
US5866536A (en) * 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US7049283B2 (en) * 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents
US20060217313A1 (en) * 2001-08-17 2006-09-28 Moise Azria 5-CNAC as oral delivery agent for parathyroid hormone fragments

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5118667A (en) * 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
US5955574A (en) * 1995-07-13 1999-09-21 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A. Analogs of parathyroid hormone
US5723577A (en) 1995-07-13 1998-03-03 Biomeasure Inc. Analogs of parathyroid hormone
EP1015008B1 (de) 1997-02-07 2015-08-05 Emisphere Technologies, Inc. Verbindungen und zusammensetzungen zur administration aktiver stoffe
SE9702401D0 (sv) 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
DE19915272A1 (de) * 1999-04-03 2000-10-05 Vetter & Co Apotheker Spritze für medizinische Zwecke
ATE288415T1 (de) * 1999-04-05 2005-02-15 Emisphere Tech Inc Dinatrium-salze, monohydrate und ethanol-solvate
WO2001032201A2 (en) 1999-10-29 2001-05-10 Eli Lilly And Company A pharmaceutical composition having high cell membrane permeability
NZ529439A (en) 2001-06-01 2005-11-25 Novartis Ag Method for orally administering parathyroid hormone (PTH)
US7318925B2 (en) * 2003-08-08 2008-01-15 Amgen Fremont, Inc. Methods of use for antibodies against parathyroid hormone

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4692433A (en) * 1983-10-12 1987-09-08 The Regents Of The University Of California Method and composition for regulating serum calcium levels of mammals
US5364840A (en) * 1989-12-05 1994-11-15 Vical, Inc. Synthetic calcitonin peptides
US5620708A (en) * 1993-02-22 1997-04-15 Alza Corporation Compositions and methods for the oral delivery of active agents
US5866536A (en) * 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US7049283B2 (en) * 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents
US20060217313A1 (en) * 2001-08-17 2006-09-28 Moise Azria 5-CNAC as oral delivery agent for parathyroid hormone fragments

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050054557A1 (en) * 2002-05-09 2005-03-10 Goldberg Michael M. Compositions for delivering parathyroid hormone and calcitonin
US20090264368A1 (en) * 2002-05-09 2009-10-22 Emisphere Technologies, Inc. Compositions for delivering parathyroid hormone and calcitonin
US20070219132A1 (en) * 2005-11-10 2007-09-20 Board Of Control Of Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
US7994129B2 (en) 2005-11-10 2011-08-09 Michigan Technological University Methods of using black bear parathyroid hormone
US8987201B2 (en) 2009-12-07 2015-03-24 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
WO2012130193A1 (en) 2011-03-31 2012-10-04 Zentiva, K.S. Non-covalent soluble complexes of teriparatide with polysaccharides and a dosage form of teriparatide for oral administration
WO2018043942A1 (ko) * 2016-08-30 2018-03-08 목포대학교산학협력단 위장관 흡수증진제를 함유하는 부갑상선 호르몬의 경구 투여 제형

Also Published As

Publication number Publication date
PL211976B1 (pl) 2012-07-31
CN1512892A (zh) 2004-07-14
CZ307145B6 (cs) 2018-02-07
WO2002098453A2 (en) 2002-12-12
NZ529439A (en) 2005-11-25
PT1397156E (pt) 2007-05-31
KR101320817B1 (ko) 2013-10-21
KR20090116836A (ko) 2009-11-11
AU2006225157B2 (en) 2009-04-23
ECSP034858A (es) 2004-01-28
CO5540323A2 (es) 2005-07-29
BRPI0209748B1 (pt) 2015-11-24
KR20120065429A (ko) 2012-06-20
EP1397156A2 (de) 2004-03-17
SK14752003A3 (sk) 2004-06-08
KR20040007617A (ko) 2004-01-24
ZA200308625B (en) 2004-07-13
US20080119411A1 (en) 2008-05-22
BR0209748A (pt) 2004-07-27
CA2446929A1 (en) 2002-12-12
HUP0400120A2 (hu) 2005-04-28
RU2003136733A (ru) 2005-05-20
JP5073153B2 (ja) 2012-11-14
RU2300392C2 (ru) 2007-06-10
NO20035133L (no) 2003-11-18
ATE356631T1 (de) 2007-04-15
PL364089A1 (en) 2004-12-13
CA2446929C (en) 2013-04-09
HU229613B1 (en) 2014-03-28
EP1397156B1 (de) 2007-03-14
CN101837120A (zh) 2010-09-22
WO2002098453A3 (en) 2003-07-31
CZ20033232A3 (cs) 2004-06-16
AU2002344371B2 (en) 2006-06-29
DE60218842T2 (de) 2007-12-20
SK287697B6 (sk) 2011-06-06
US8153587B2 (en) 2012-04-10
JP2005500277A (ja) 2005-01-06
ES2282436T3 (es) 2007-10-16
MXPA03011027A (es) 2004-03-19
AU2006225157A1 (en) 2006-10-19
IL158777A0 (en) 2004-05-12
JP2010189423A (ja) 2010-09-02
HUP0400120A3 (en) 2012-09-28
NO20035133D0 (no) 2003-11-18
IL158777A (en) 2012-06-28
DE60218842D1 (de) 2007-04-26
NO330093B1 (no) 2011-02-14

Similar Documents

Publication Publication Date Title
US8153587B2 (en) Orally administering parathyroid hormone and calcitonin
US9272040B2 (en) 5-CNAC as oral delivery agent for parathyroid hormone fragments
US20090264368A1 (en) Compositions for delivering parathyroid hormone and calcitonin
AU2002344371A1 (en) Orally administering parathyroid hormone and calcitonin
AU2002333443A1 (en) 5-CNAC as oral delivery agent for parathyroid hormone fragments

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION